PMID- 29500656
OWN - NLM
STAT- MEDLINE
DCOM- 20191106
LR  - 20191106
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 32
IP  - 9
DP  - 2018 Sep
TI  - Clinicopathological features and endoscopic findings of HER2-positive gastric 
      cancer.
PG  - 3964-3971
LID - 10.1007/s00464-018-6138-8 [doi]
AB  - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) expression in gastric 
      cancer is highly heterogeneous. Therefore, it is important to take endoscopic 
      samples from appropriate tumor sites. METHODS: Between January 2008 and April 
      2015, patients with gastric or gastroesophageal junction cancer with 
      histologically confirmed adenocarcinoma were included. Surgical samples or 
      endoscopic biopsy samples were examined for HER2 using immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH). Tissues were considered to be HER2 
      positive when either assessment revealed either an IHC score of 3+ or an IHC 
      score of 2+ accompanied by a positive FISH result. Endoscopic findings were 
      retrieved in all cases where available, and we examined the portion from which a 
      biopsy was obtained. RESULTS: Out of the 612 patients included in the study, 104 
      (17%) were HER2 positive. The proportion of HER2-positive gastric tumors with 
      differentiated (vs. undifferentiated) histology was significantly higher (29 vs. 
      6%, respectively; p < 0.001). The HER2-positive rate of papillary adenocarcinomas 
      (vs. tubular) was particularly high (62%, 8/13; p = 0.023). The proportion of 
      HER2-positive gastric tumors of Borrmann classification 0 or 1 was significantly 
      higher than that of tumors of classified as 2, 3, or 4 (45 vs. 16%, respectively; 
      p < 0.001). The HER2-positive rates per biopsy specimen from the superficial 
      spreading portion, ulcer mound, ulcer bed, and mass portion were 100, 91, 45, and 
      100%, respectively. CONCLUSIONS: HER2-positive gastric cancer tends to be 
      associated with a differentiated histology, particularly papillary 
      adenocarcinoma, and a Borrmann classification of 0 or 1 tumors. Based on these 
      endoscopic findings, it is important to recognize the superficial spreading 
      portion and the mass portion of gastric malignancies.
FAU - Oono, Yasuhiro
AU  - Oono Y
AUID- ORCID: 0000-0002-8387-0372
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center Hospital 
      East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. yohno@east.ncc.go.jp.
FAU - Kuwata, Takeshi
AU  - Kuwata T
AD  - Division of Pathology, National Cancer Center Hospital East, Kashiwa, Japan.
FAU - Takashima, Kenji
AU  - Takashima K
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center Hospital 
      East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Yoda, Yusuke
AU  - Yoda Y
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center Hospital 
      East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Ikematsu, Hiroaki
AU  - Ikematsu H
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center Hospital 
      East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
FAU - Shitara, Kohei
AU  - Shitara K
AD  - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer 
      Center Hospital East, Kashiwa, Japan.
FAU - Kinoshita, Takahiro
AU  - Kinoshita T
AD  - Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa, Japan.
FAU - Yano, Tomonori
AU  - Yano T
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center Hospital 
      East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180302
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*metabolism/*pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Esophagogastric Junction/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*metabolism/*pathology
OTO - NOTNLM
OT  - Endoscopic findings
OT  - Gastric cancer
OT  - HER2
EDAT- 2018/03/04 06:00
MHDA- 2019/11/07 06:00
CRDT- 2018/03/04 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2018/02/23 00:00 [accepted]
PHST- 2018/03/04 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
PHST- 2018/03/04 06:00 [entrez]
AID - 10.1007/s00464-018-6138-8 [pii]
AID - 10.1007/s00464-018-6138-8 [doi]
PST - ppublish
SO  - Surg Endosc. 2018 Sep;32(9):3964-3971. doi: 10.1007/s00464-018-6138-8. Epub 2018 
      Mar 2.